Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Association Between Peripheral Neuropathy Induced by Oxaliplatin at First-line Chemotherapy and Efficacy of Paclitaxel at Second-line Chemotherapy in Patients With Advanced Gastric Cancer

HIRONORI FUJII, SHIORI SADAKA, KANAE AJISAWA, NAOKI OKUMURA, AKITAKA MAKIYAMA, HIROTOSHI IIHARA, ITARU YASUFUKU, KOICHI OHATA, RYO KOBAYASHI, YOSHIHIRO TANAKA, HIDEKI HAYASHI and AKIO SUZUKI
Anticancer Research September 2022, 42 (9) 4581-4588; DOI: https://doi.org/10.21873/anticanres.15961
HIRONORI FUJII
1Department of Pharmacy, Gifu University Hospital, Gifu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: h_fujii@gifu-u.ac.jp
SHIORI SADAKA
1Department of Pharmacy, Gifu University Hospital, Gifu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KANAE AJISAWA
2Laboratory of Community Pharmaceutical Practice and Science, Gifu Pharmaceutical University, Gifu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NAOKI OKUMURA
3Department of Gastroenterological Surgery/Pediatric Surgery, Gifu University Graduate School of Medicine, Gifu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AKITAKA MAKIYAMA
3Department of Gastroenterological Surgery/Pediatric Surgery, Gifu University Graduate School of Medicine, Gifu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROTOSHI IIHARA
1Department of Pharmacy, Gifu University Hospital, Gifu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ITARU YASUFUKU
3Department of Gastroenterological Surgery/Pediatric Surgery, Gifu University Graduate School of Medicine, Gifu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOICHI OHATA
1Department of Pharmacy, Gifu University Hospital, Gifu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RYO KOBAYASHI
1Department of Pharmacy, Gifu University Hospital, Gifu, Japan;
4Laboratory of Advanced Medical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHIHIRO TANAKA
3Department of Gastroenterological Surgery/Pediatric Surgery, Gifu University Graduate School of Medicine, Gifu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIDEKI HAYASHI
2Laboratory of Community Pharmaceutical Practice and Science, Gifu Pharmaceutical University, Gifu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AKIO SUZUKI
1Department of Pharmacy, Gifu University Hospital, Gifu, Japan;
4Laboratory of Advanced Medical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Although peripheral neuropathy (PN) is a common adverse event in patients treated with oxaliplatin as first-line chemotherapy (1st-OX) for advanced gastric cancer, the effect of PN on the efficacy of paclitaxel at second-line chemotherapy (2nd-PTX) remains unclear. We investigated the association between PN induced by 1st-OX and efficacy of 2nd-PTX in patients with advanced gastric cancer (AGC). Patients and Methods: The study subjects were patients with AGC who received 1st-OX followed by 2nd-PTX at Gifu University Hospital between January 2015 and December 2019. Primary outcome was time to treatment failure (TTF) of 2nd-PTX. Secondary outcomes included overall survival (OS), response rate and adverse events during the period of 2nd-PTX. The association between incidence of grade ≥2 peripheral neuropathy (G2PN) and TTF or OS was also evaluated using Cox proportional hazards analysis. Results: A total of 54 patients with AGC who received 1st-OX followed by 2nd-PTX were eligible. Incidence rates of G2PN at the start of 2nd-PTX was 20.3% (11/54). Median duration of TTF and OS were not significantly longer in patients with G2PN than in those without it (TTF: 4.7 months vs. 3.7 months, p=0.264, OS: 10.6 months vs. 8.5 months, p=0.706). Cox proportional hazards analysis indicated that there was no significant relationship between the incidence of G2PN and TTF, or between the incidence of G2PN and OS. However, development of grade ≥3 PN was significantly higher in patients with G2PN than in those without it (45.5% vs. 2.3%, p<0.001). Conclusion: G2PN induced by 1st-OX may not affect efficacy of 2nd-PTX in patients with AGC but could be a risk for grade ≥3 PN of 2nd-PTX.

Key Words:
  • Paclitaxel
  • peripheral neuropathy
  • gastric neoplasms
  • survival
  • Received July 20, 2022.
  • Revision received July 28, 2022.
  • Accepted July 29, 2022.
  • Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
View Full Text
PreviousNext
Back to top

In this issue

Anticancer Research: 42 (9)
Anticancer Research
Vol. 42, Issue 9
September 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Association Between Peripheral Neuropathy Induced by Oxaliplatin at First-line Chemotherapy and Efficacy of Paclitaxel at Second-line Chemotherapy in Patients With Advanced Gastric Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 14 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Association Between Peripheral Neuropathy Induced by Oxaliplatin at First-line Chemotherapy and Efficacy of Paclitaxel at Second-line Chemotherapy in Patients With Advanced Gastric Cancer
HIRONORI FUJII, SHIORI SADAKA, KANAE AJISAWA, NAOKI OKUMURA, AKITAKA MAKIYAMA, HIROTOSHI IIHARA, ITARU YASUFUKU, KOICHI OHATA, RYO KOBAYASHI, YOSHIHIRO TANAKA, HIDEKI HAYASHI, AKIO SUZUKI
Anticancer Research Sep 2022, 42 (9) 4581-4588; DOI: 10.21873/anticanres.15961

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Association Between Peripheral Neuropathy Induced by Oxaliplatin at First-line Chemotherapy and Efficacy of Paclitaxel at Second-line Chemotherapy in Patients With Advanced Gastric Cancer
HIRONORI FUJII, SHIORI SADAKA, KANAE AJISAWA, NAOKI OKUMURA, AKITAKA MAKIYAMA, HIROTOSHI IIHARA, ITARU YASUFUKU, KOICHI OHATA, RYO KOBAYASHI, YOSHIHIRO TANAKA, HIDEKI HAYASHI, AKIO SUZUKI
Anticancer Research Sep 2022, 42 (9) 4581-4588; DOI: 10.21873/anticanres.15961
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Triage Process at Endoscopy With ColonView Fecal Immunochemical Test (FIT) Will Enhance Diagnostic Accuracy (DA) of Colorectal Cancer Screening
  • Laparoscopic Colorectal Cancer Surgery for Patients With Severe Chronic Heart Failure
  • Clinical Impact of Prehabilitation on Elective Laparoscopic Surgery in Frail Octogenarians With Colorectal Cancer
Show more Clinical Studies

Similar Articles

Keywords

  • paclitaxel
  • peripheral neuropathy
  • gastric neoplasms
  • survival
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire